| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRTX | Common Stock | Purchase | $3.39M | +27.8K | +1.42% | $121.99 | 1.98M | Jun 29, 2022 | By Sofinnova Venture Partners X, LP | F2, F3 |
| transaction | KRTX | Common Stock | Purchase | $497K | +4.04K | +0.2% | $122.95 | 1.98M | Jun 29, 2022 | By Sofinnova Venture Partners X, LP | F3, F4 |
| transaction | KRTX | Common Stock | Purchase | $852K | +6.83K | +0.34% | $124.73 | 1.99M | Jun 29, 2022 | By Sofinnova Venture Partners X, LP | F3, F5 |
| transaction | KRTX | Common Stock | Purchase | $1.14M | +9.13K | +0.46% | $125.00 | 2M | Jun 29, 2022 | By Sofinnova Venture Partners X, LP | F3 |
| transaction | KRTX | Common Stock | Purchase | $5.88M | +48.1K | +2.4% | $122.27 | 2.05M | Jun 30, 2022 | By Sofinnova Venture Partners X, LP | F3, F6 |
| transaction | KRTX | Common Stock | Purchase | $2.98M | +24.2K | +1.18% | $123.39 | 2.07M | Jun 30, 2022 | By Sofinnova Venture Partners X, LP | F3, F7 |
| holding | KRTX | Common Stock | 683 | Jun 29, 2022 | By Sofinnova Synergy Master Fund, LP | F1 |
| Id | Content |
|---|---|
| F1 | All shares held by Sofinnova Synergy Master Fund, LP (the "Fund"). Sofinnova Synergy Fund GP, LLC (the "GP"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $121.50 to $122.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| F3 | All shares held by Sofinnova Venture Partners X, LP ("SVP X"). Sofinnova Management X, LLC (the "SM X"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.755 to $123.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $124.00 to $124.99, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.145 to $122.962, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (6) to this Form 4. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $123.21 to $123.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (7) to this Form 4. |